Samsung Biologics has signed a contract worth 111.2 billion won with an undisclosed U.S. pharmaceutical firm to provide ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its ...

Samsung Biologics earns spot on Dow Jones Sustainability Index for fourth year Samsung Biologics maintains its position in ...

Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its ...

Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis.

Threading quality into every step: One-stop manufacturing at Samsung Biologics Samsung Biologics, a fully integrated CDMO, is dedicated to ensuring high-quality production through its ...

Samsung Biologics was recognized for its dedication to embed sustainable business practices across its operations, particularly robust environmental efforts, including progress toward achieving ...

INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day ...

Samsung invests in Generate to advance AI-driven protein therapeutics discovery: Incheon, South Korea Saturday, December 21, 2024, 17:00 Hrs [IST] Samsung announced that it has in ...